Binaytara shared a post on LinkedIn:
”One of the most useful things Dr. Paolo Tarantino said during his keynote at our Detroit 2026 Hematology and Oncology Practice Symposium was something the field doesn’t say often enough:
ADCs are not the magic bullets we sometimes describe them as. Most still cause fatigue, nausea, alopecia, and neutropenia.
The tolerability profile is often better than sequential single-agent chemotherapy, but ‘better tolerated’ is not the same as ‘well tolerated.’ Patient counseling needs to reflect that distinction – especially as these agents move into earlier lines and adjuvant settings, where patients may be on therapy for longer and have higher expectations of quality of life.
Curious how others are approaching the side-effect conversation now that ADCs are first-line in more indications.
Read more about Dr Tarantino’s keynote.”
Other Articles Featuring Binaytara on Oncodaily.